PTAB Gives Sanofi First-Ever Early Feedback On Amendments
Sanofi's proposed adjustments to insulin patents being challenged by Mylan likely won't pass muster, the Patent Trial and Appeal Board has said in its first-ever guidance under a new program that...To view the full article, register now.
Already a subscriber? Click here to view full article